Translational Regenerative Medicine

Convening the Regenerative Medicine Community

• April 6-8, 2010
• Twin City Quarter
• Winston-Salem, NC

Drivers and Strategies for Healthcare Innovation and Personalized Medicine

• April 6th: Registration and Opening Reception
• April 7th: Regenerative Medicine: Fulfilling the Promise of Healthcare Innovation and Personalized Medicine
• April 8th: Meeting Clinical Needs through Best Practices and Business Models. Afternoon Venture Forum

Featuring Leaders from:

Acorda Therapeutics Advanced BioHealing Advanced Cell & Gene Therapy Advanced Cell Technology Aldagen America Stem Cell, Inc. ATCC Athersys GE Healthcare Histogen iPierian Integra Life Technologies Novartis Institutes for Biomedical Research Organogenesis Pfizer Stem Cell Therapeutics Corp Stratatech Tengion Transgeneron DeNovo Ventures Excel Venture Management InterSouth Partners Livingston Capital Proteus Ventures Quaker BioVentures

Safeguard Scientifics Juvenile Diabetes Research Foundation Fast Forward Armed Forces Institute for Regenerative Medicine (AFIRM) California Institute for Regenerative Medicine (CIRM) Harvard Stem Cell Institute Northwestern University, Feinberg Neuroscience Institute Northwestern University School of Medicine Tokyo Women’s Medical University, Institute of Advanced Biomedical Engineering and Science University of Kansas, Institute for Advancing Innovation University of Miami Miller School of Medicine, Institute for Diabetes Research University of Washington Virginia Tech Wake Forest Institute for Regenerative Medicine (WFIRM) U.S. Army Medical Research U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) The Aspen Institute Center for Health Transformation Genetics Policy Institute Greenleaf Health, LLC Kauffman Foundation Hogan & Hartson Holland & Knight Adjuvant Global Advisors Cell Therapy Group

About the Forum

The Translational Regenerative Medicine Forum is the premiere event for leaders in regenerative medicine translation, representing academic research, clinical, healthcare policy, regulatory, reimbursement, investment and biotechnology industry interests. In order to facilitate business development opportunities and investment, the meeting will include a venture forum featuring 15 regenerative medicine companies

Corporate Registration

• $850.00 through March 15, 2010
• $975.00 after March 15, 2010 or Onsite

Academic/Not-for-Profit Government Registration

• $495.00

For more information about the inaugural 2010 conference, please contact Jon Obermeyer at the Regenerative Medicine Foundation: 336.509.3080 or

2010 Program Committee

• Tim Bertram, Tengion
• Lee Buckler, Cell Therapy Group
• Scott R. Burger, MD, Advanced Cell & Gene Therapy
• Jeff Karan, Proteus Ventures
• Lesa Mitchell, Kauffman Foundation
• Michelle McMurry, The Aspen Institute
• Morrie Ruffin, Adjuvant Global Advisors
• Steve Binion, Regulatory Affairs, BD
• Michael Werner, Holland & Knight
• David F. Williams, D.Sc., FREng., Wake Forest Institute for Regenerative Medicine
• James Yoo, M.D., Ph.D., Wake Forest Institute for Regenerative Medicine

Promotional Partners

Tissue Engineering and Regenerative Medicine International Society (TERMIS) www.termis.org
Genetics Policy Institute www.genpol.org